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BACKGROUND: Childhood acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy in Indonesia and often treated by 
methotrexate (MTX). Though it can be cured in 30-60% 
of patients, MTX resistance remains the major cause of 
treatment  failure  in  childhood  ALL.  Previous sudies 
showed  that  its  anti-leukemic  property  was  moderated 
by  MTX  ability to inhibitmethylene tetra hydrofolate 
reductase (MTHFR) and thymidylate synthase (TS) in 
folate metabolism. This study  investigates  the  correlation 
between  MTHFR  and TS polymorphism and MTX 
resistance in ALL children.
METHODS: A total of 155 subjects obtained from all 
subjects prior to chemotherapy. DNA from blood samples 
were extracted and underwent polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) 
to evaluate MTHFR C677T and TS 5’-UTR 3R/3R 
polymorphism.
RESULTS: There was significant correlation between 
MTHFR C677T and TS 5’-UTR 3R/3R gene polymorphism 
with MTX resistance. Subjectswith MTHFR C677T and TS 
5’-UTR 3R/3R gene polymorphism were 4 times (p=0.007) 
and 6.4 times (p=0.001) more likely to be MTX resistant 
than those without gene polymorphisms, respectively.
CONCLUSION: MTHFR C677T andTS 5’-UTR 3R/3R 
represent dominant gene polymorphism related to MTX 
resistance in childhood ALL.
KEYWORDS: gene polymorphism, folate metabolism, 
acute lymphoblastic leukemia
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Abstract
Introduction
Acute lymphoblastic leukemia (ALL) is consider the most 
common malignancy in pediatric population, accounting for 
approximately 30% of all cancer in children, and current 
optimal use of anti-leukemic agents have pushed its cure 
rate above 85%.(1) An important cytostatic drug used in the 
treatment of ALL is anti-folate methotrexate (MTX) which 
inhibits DNA synthesis. Folate are important component 
for synthesis of purine and pyrimidine, thus is essential 
for normal cell growth, DNA replication and repair. The 
polyglutamylated form of MTX acts as an inhibitor of 
enzyme thymidylate synthase (TS) and is and is an important 
enzymes, its gene is located in chromosome 18 and catalyses 
the conversion of deoxyuridylate monophosphate (dUMP) 
to deoxy thymidylate monophosphate (dTMP) thus TS is 
the key enzyme in de novo DNA synthesis. TS has unique 
tandem repeat sequence in the 5’ untranslated region (UTR) 
immediately upstream of the ATG codon initiation start site 
that has been shown to be polymorphic, containing either 
two or three 28-bp repats. The second important enzymes 
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in MTX is methylenetetrahydrofolate reductase (MTHFR) 
which catalyse the irreversible conversion of 5,10-MTHF 
into 5-MTHF in intracellular folate homeostasis. MTHFR 
gene is located in chromosome 1p and is subject to several 
polymorphisms. One of them a mutation C-T at nucleotide 
position 677 which result in an alanine to valine substitution.
 Around one-third of all patients experience treatment 
failure (2-5), probably caused by resistance to MTX, a 
chemotherapy used in ALL treatment (6). It is hypothesized 
that MTX resistance is caused by gene polymorphisms 
encoding various enzymes involved in folate metabolism, 
e.g., MTHFR and TS. In fact, these gene polymorphisms 
exist among different ethnic variations.(7-11) In Indonesia, 
the incidence of TS5’-UTR 3R/3R polymorphisms was 
76.3%  compared  to  33.1% in  Caucasian  populations.
(12) The incidence of MTHFR C677T polymorphisms in 
children without leukemia is also high in the Indonesian 
population.(13)
 Meanwhile, MTHFR C677T and TS 5’-UTR 3R/3R 
gene polymorphismscould disrupt MTX activities by 
impeding the ability of MTX to suppress the enzymes 
responsible for lymphoblast DNA synthesis. Thus, DNA 
synthesis continues, resulting in MTX resistance. This study 
will investigate the correlation between MTHFR C677T and 




This study involved pediatric ALL patients, admitted to Dr. 
Soetomo General Hospital, Surabaya, from January 2013 to 
July 2016. Inclusion criteria werechildren aged 0-16 years 
old, ALL type L1 and L2 based on French-American-British 
(FAB) classification, no prior cytostatic chemotherapy 
treatment for leukemia, and regular participation in a 
chemotherapy treatment protocol. Subjects who met the 
inclusion criteria were included to the study and underwent 
treatmentaccording to National ALL Protocol 2006.(14)
After 6 weeks, subjects were evaluated by bone marrow 
aspiration and classified as resistant if lymphoblast were 
more than 5%. Ethical clearance was given by the Ethical 
Research Commission of Dr. Soetomo General Hospital, 
Surabaya, No. 50/Panke.KKE/2007. 
DNA Extraction
Prior to the chemotherapy treatment, blood samples from 
study  subjects  were  obtained  and  stored  in a refrigerator 
using  filter  paper.   Blood   samples   from   the   filter 
paper were  diluted in 0.5 mL Tris-EDTA (TE) buffer (Cat. 
No. 93239, Sigma Aldrich,  St. Louis,  Missouri,  USA). 
Mixture was centrifuged  using  SL  16  centrifuge  (Thermo 
Fisher Scientific,  Waltham,  Massachusetts,  USA)  at 
10,000-13,000 rpm. Pellet was suspended using vortex 
mixer (Fisher Scientific, Hampton, New Hampshire, 
USA) in 0.5 mL TE buffer. Samples were incubated using 
Thermo Scientific IMH100 Heratherm Advanced Protocol 
Microbiological Incubator (Thermo Fisher Scientific) in 
56oC for 45 minutes, and again incubated in 95oC for 45 
minutes. 
PCR Technique
PCR was conducted using BioRad DNA Engine PTC-200 
Peltier Thermal Cycler (Conquer Scientific, San Diego, 
California, USA). Primary sequence used for MTHFR C677T 
was 5'-CAG TCC CTG TGG TCT CTT CAT-3' (forward) 
and 5'-AGG ACG GTG CGG TGA GAG TG-3' (reverse), 
while for TS 5’-UTR 3R/3R 28 bp repeat was 5'-GTG GCT 
CCT GCG TTT CCC CC-3' (forward) and 5'-GGC TCC 
GAG CCG GCC ACA GGC ATG GCG CGG-3' (reverse) 
(synthesized by Eurogentec Biotechnology Company, 
Liege, Belgium). Mixture for MTHFR C677T contained 
Invitrogen Platinum Taq DNA Polymerase (Thermo Fisher 
Scientific), forward and reverse primer, and dNTP (Cat. 
No. R0181, Thermo Fisher Scientific). Mixture for TS 5’ 
UTR 3R/3R 28 bp repeat contained HotStarTaqPlusDNA 
Polymerase (Cat. No. 203203, Qiagen, Hilden, Germany), 
forward and reverse primer, dNTP, and NeXtal Stock 
Dimethyl sulfoxide (Cat. No. 133037, Qiagen).
RFLP Technique
HinfI restriction enzyme (Catalog No. ER0801, Thermo 
Fisher Scientific) was used for MTHFR C677T and HaeIII 
restriction enzyme (Catalog No. ER0151, Thermo Fisher 
Scientific) was used for TS 5’-UTR 3R/3R 28 bp. Mixture 
was kept overnight before analysis. Gene, DNA fragment 
sizes after RFLP: MTHFR C677T wild type undigested 328 
bp. Mutant digested 176 np and 152 bp,  while TS 5’-UTR 
3R/3R 243 bp.
DNA Analysis
Gen polymorphism for TS 5’-UTR 3R/3R 28 bp was 
analyzed using ABI Prism 3100-Avant Genetic Analyzer 
(Applied Biosystems Biotechnology Company, Foster City, 
California, USA). Gen polymorphism for MTHFR C677T 
was analyzed using LightCycler 480 Instrument II (Roche 
Diagnostics, Basel, Switzerland).
Gene Polymorphism in Methotrexate-Resistant Childhood ALL (Ugrasena IDG, et al.)Indones Biomed J. 2020; 12(2): 177-82DOI: 10.18585/inabj.v12i2.1109
179
Gel Electrophoresis
PCR and RFLP products could be seen by 3% agarose 
gel electrophoresis and by adding ethidium bromide. 
Documentation was done using the Gel Doc system (Bio-
Rad Laboratories, Feldkirchen, Germany).
Statistical Analysis
Statistical analysis was conducted using IBM SPSS version 
22 (IBM Corporation, Armonk, New York, USA). To see the 
relationship between MTX resistance and MTHFR C677T 
and TS5’-UTR 3R/3R gene polymorphisms, the chi-square 
test and Fisher's absolute test were performed. To study 
the effects of each type of gene polymorphism on MTX 
resistance, multiple logistic regression tests were used. 
To determine the effects of both single and combination 
polymorphisms on MTX chemotherapy resistance, logistic 
regression tests wereused.
Results
From a total of 167 samples involved in this study, only 155 
subjects completed the study. Six subjects dropped out, 4 
subjects refused the protocol therapy, and 2 other subjects 
were excluded due to incomplete medical records. PCR and 
RFLP results of MTHFR C677T and TS 5’-UTR 3R/3R 
polymorphisms can be seen in Figure 1 and Figure 2.
 The average age was 5.67 years, the youngest 
subject was 8 months old and the oldest was 14 years old. 
Statistical tests on MTX resistance showed no correlation 
with age groups (p>0.05) (Table 1). According to gender 
and lymphoblast cell morphology, there was no relationship 
between gender and cell morphology toward MTX 
resistance.
 Table 2 showed that subjects with MTHFR C677T 
gene polymorphism were more likely to be resistant to MTX 
Figure 1. PCR-RFLP results of wildtype MTHFR CTH7 gene polymorphism produced 328 bp fragments. Heterozygotes produced 
328 bp, 176 bp, and 152 bp fragments, whereas homozygous mutants produced 176 bp and 152 bp, positive control LS 174 T selline. This 
examination used a 100 bp DNA ladder marker.
(84.2%) compared to those without gene polymorphism 
(60.7%). Similar results were also seen on Table 3 in which 
subjects with TS 5’-UTR 3R/3R gene polymorphism were 
more likely to be resistant to MTX (71.3%) compared to 
those without polymorphism (31.6%). Multiple logistic 
regression tests showed that polymorphism of TS 5’-UTR 
3R/3R and MTHFR C677T had significant correlation with 
MTX resistance. ALL subjects with TS 5’-UTR 3R/3R 
polymorphism had 6.4 times greater probability of being 
MTX resistant than patients without TS 5’-UTR 3R/3R 
polymorphism (p=0.001). ALL patients with MTHFR 
C677T gene polymorphism were 4 times more likely to 
be resistant to MTX chemotherapy compared to patients 
who did not have the MTHFR C677T gene polymorphism 
(p=0.007). Therefore, this result supports our hypothesis that 
MTHFR C677T and TS 5’-UTR 3R/3R gene polymorphism 
correlates with MTX resistance in ALL patients.
Discussion
Leukemia patients who apparently fail to exhibit a 
therapeutic response (remission or complete remission) can 
be referred to as resistant to anti-leukemia drugs (clinical 
drug resistance).(5,15,16) In the pediatric population, ALL 
is the most common malignancy encountered in daily 
practice. One of the essential drugs used in ALL is MTX, 
which works as a folate antagonist to inhibit DNA synthesis, 
and resistance toward MTX does exist.
 This phenomenon is often found in pediatric patients 
with ALL who have poor prognostic factors; for instance, 
maleshave worse prognosis than females and younger 
patients have a worse prognosis than older patients.
(17,18) However, in this study, it was not proven that age 
and gender were related to MTX resistance.In correlation 
with lymphoblast morphology, the results of this study 
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Figure 2. PCR results of TSER 5’-UTR 28 bp 2R/2R polymorphism produced 215 bp fragments, 2R/3R variants produced 215 bp 
and 243 bp fragments, 3R/3R produced 243 bp fragments, whereas 3R/4R produced fragments of 215 bp, 243 bp, and 300 bp. This 





<1 year 0 (0) 1 (100) 0.721
1-10 years 48 (34.8) 90 (65.2)
>10 years 4 (25) 12 (75)
Male 32 (36.8) 55 (63.2) 0.428
Female 20 (29.4) 48 (70.6)
ALL type-L1 50 (34.7) 94 (65.3) 0.357






Table1. Correlation between basic characteristics of samples and MTX 
resistance in childhood ALL.
were similar to those of previous studies that found no 
relationship between leukemia based on FAB classification 
and MTX resistance.(3)
 Studies investigating MTX resistance in childhood 
ALL have mostly been carried out in laboratory base 
using cultured cells (8) and experimental animals.(19,20) 
However, studies using cultured cells and experimental 
animals have been unable to solve the problem of MTX 
resistance. Thus, we conducted our study using human 
subjects. 
 MTHFR plays an important role in intracellular folate 
homeostasis through its involvement in two pathways of 
folate metabolism, which arein the synthesis of methionine 
and S-adenosyl methionine (SAM) and through thymidylate 
synthase needed for DNA synthesis. Polymorphisms in the 
gene that encodes MTHFR usually occur at the nucleotide 
677 position where alanine is replaced by valine (C677T), 
and it has been proven that polymorphism in the MTHFR 
C677T gene will cause enzyme activity to decrease 
significantly.(10,21-24) If there is a polymorphism in the 
MTHFR gene, the activity of the MTHFR enzyme will 
reduce, causing a decrease in the number of 5-MTHF 
due to an increase in the amount of homocysteine in the 
blood (hyperhomocysteinemia), which in turn will lead 
to increased  toxicity  or  failure  of  chemotherapy.  In 
addition to the decrease of 5-MTHF, decreased activity 
of the MTHFR enzyme also causes an increase in the 
amount of 5,10-MTHF, which provides a methyl group in 
the formation of thymidylate, a precursor needed for DNA 
synthesis. As a result, DNA synthesis continues and thus 
causes resistance.(14,25-32)
 TS catalyzes dUMP to dTMP during process of 
DNA synthesis. TS enzyme polymorphism is a repeated 
sequence for every 28 base pairs (tandem repeat sequence) 
in the 5'UTR.(33) Polymorphism of the genes encoding the 
TS enzyme will increase gene expression in TS (33,34), 






Negative 46 (39.3) 71 (60.7) 117 (75.5)
Positive 6 (15.8) 32 (84.2) 38 (24.5)
Total 52 (33.5) 103 (66.5) 155 (100)
Sample
TotalPolymorphismMTHFR C677T
Table 2. Cross-table of MTX resistance and gene polymorphism of MTHFR 
C677T in childhood ALL.





Negative 13 (68.4) 6 (31.6) 19 (12.3)
Positive 39 (28.7) 97 (71.3) 136 (87.7)





Table 3. Cross-table of MTX resistance and gene polymorphism of TS5’-UTR 
3R/3R in childhood ALL.
Chi-square test = 10.097 (p=0.001).
stimulating conversion ofdUMP to dTMP, increasing 
DNA synthesis, and ultimately leading to MTX resistance.
(12,30,35)
 Furthermore, this study also found that 31.6% of 
ALL patients resistant to MTX did not display TS5’-
UTR 3R/3R polymorphism. This resistance to MTX can 
be caused by other gene polymorphisms, such as reduced 
folate carrier (RFC) transport, dihydrofolate reductase 
(DHFR), folypolyglutamate hydrolase (FPGH), and 
folypolyglutamatesynthetase (FPGS).(36) Combinations of 
several  polymorphisms  of  hydrolase  genes  involved in 
folate  metabolism  should  also  be  investigated  in  further 
studies.
Conclusion
It is concluded that ALL patients with TS 5’-UTR 3R/3R 
polymorphism had 4 times greater probability of  being MTX 
resistant than without TS 5’-UTR 3R/3R polymorphism, 
and also patients with MTHFR C677T gene polymorphism 
were 4 times more likely to be resistant to MTX. The most 
dominant gene causing MTX resistance is TS 5’-UTR 
3R/3R. 
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